ArticlePloS one2015
Atypical antipsychotics as augmentation therapy in anorexia nervosa.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- The Efficacy of Pharmacological Treatment of Depression in Anorexia Nervosa and Underweight Patients: A Systematic Review.European eating disorders review : the journal of the Eating Disorders Association · 2026Pooled it
- Inpatient treatments for adults with anorexia nervosa: a systematic review of literature.Eating and weight disorders : EWD · 2024Pooled it
- Descriptions of Disordered Eating in German Psychiatric Textbooks, 1803-2017.Frontiers in psychiatry · 2020Pooled it
- A Meta-Analysis of Dropout and Metabolic Effects of Antipsychotics in Anorexia Nervosa.Frontiers in psychiatry · 2020Pooled it
- Use of atypical antipsychotics in individuals with anorexia nervosa.The mental health clinician · 2025Article
- Olanzapine for young PEople with aNorexia nervosa (OPEN): results of a feasibility study.BMC psychiatry · 2024Article
- Psychopharmacology Review for Eating Disorders Among Children, Adolescents, and Adults.Focus (American Psychiatric Publishing) · 2024Review
- Cognitive Impulsivity in Anorexia Nervosa in Correlation with Eating and Obsessive Symptoms: A Comparison with Healthy Controls.Nutrients · 2024Article
- Atypical antipsychotic use does not impact weight gain for individuals with extreme anorexia nervosa: a retrospective case-control study.Journal of eating disorders · 2023Article
- The Nepean Belief Scale (NBS) as a tool to investigate the intensity of beliefs in anorexia nervosa: psychometric properties of the Italian version.Eating and weight disorders : EWD · 2023Article
- Pharmacotherapy, alternative and adjunctive therapies for eating disorders: findings from a rapid review.Journal of eating disorders · 2023Review
- Mediation models of anxiety and depression between temperament and drive for thinness and body dissatisfaction in anorexia nervosa.Eating and weight disorders : EWD · 2022Article
- From Desire to Dread-A Neurocircuitry Based Model for Food Avoidance in Anorexia Nervosa.Journal of clinical medicine · 2021Review
- Is aripiprazole a key to unlock anorexia nervosa?: A case series.Clinical case reports · 2020Article
- Neural Insensitivity to the Effects of Hunger in Women Remitted From Anorexia Nervosa.The American journal of psychiatry · 2020Article
- Alterations in serotonin transporter and body image-related cognition in anorexia nervosa.NeuroImage. Clinical · 2019Article
- Pharmacotherapy of eating disorders.Current opinion in psychiatry · 2017Review
- The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa.The International journal of eating disorders · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anorexia nervosa (AN) is a life-threatening and difficult to treat mental illness with the highest mortality rates of any psychiatric disorder. We aimed to garner preliminary data on the real-world use of olanzapine and aripiprazole as augmentation agents of Selective Serotonin Reuptake Inhibitors (SSRIs) in adult inpatients affected by AN. We retrospectively evaluated the clinical charts of patients who were hospitalized between 2012 and 2014. Patients were evaluated upon admission and discharge. We investigated eating symptomatology, and both general and eating psychopathology using: Hamilton Rating Scale for Anxiety, Hamilton Rating Scale for Depression, and Yale-Brown-Cornell Eating Disorders Scale. The charts of 75 patients were included in this study. The sample resulted equally distributed among those receiving SSRIs and either aripiprazole or olanzapine in addition to SSRIs. Notwithstanding a few baseline clinical differences, upon discharge all groups were significantly improved on all measures. Interestingly, aripiprazole showed the greatest effectiveness in reducing eating-related preoccupations and rituals with a large effect size. The body of evidence on medication management in AN is in dismal condition. Augmentation therapy is a well-established approach to a variety of mental disorders and it is often used in every-day clinical practice with patients affected by AN as well. Nevertheless, to date very little data is available on this topic. Results from our sample yielded promising results on the effectiveness of aripiprazole augmentation in reducing eating-related obsessions and compulsions. Randomized controlled trials are warranted to confirm these encouraging findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.